KEAP1 Monoclonal Antibody, APC-Cy7 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bsm-60935r-apc-cy7-100l |
| Product Name | KEAP1 Monoclonal Antibody, APC-Cy7 Conjugated |
| Applications |
WB
|
| Reactivity | Human, Mouse, Monkey |
| Specifications | |
| Conjugation | APC-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human KEAP1 |
| Clonality | Monoclonal |
| Clone # | 7B13 |
| Isotype | IgG |
| Concentration | 1mg/ml |
| Purification | purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 9817 |
| Swiss Prot | Q14145 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | Cytosolic inhibitor of Nrf2; INrf 2; INrf2; Keap 1; KEAP1; KEAP1_HUMAN; Kelch like ECH associated protein 1; Kelch like protein 19; Kelch-like ECH-associated protein 1; Kelch-like protein 19; KIAA0132; KLHL 19; KLHL19; MGC10630; MGC1114; MGC20887; MGC4407; MGC9454. |
| Background | Retains NFE2L2/NRF2 in the cytosol. Functions as substrate adapter protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1. Targets NFE2L2/NRF2 for ubiquitination and degradation by the proteasome, thus resulting in the suppression of its transcriptional activity and the repression of antioxidant response element-mediated detoxifying enzyme gene expression. May also retain BPTF in the cytosol. Targets PGAM5 for ubiquitination and degradation by the proteasome. |
| Application Dilution | |
| WB | 1:500-2000 |